These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31129650)

  • 1. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
    Di Paolo CT; Filippou PS; Yu Y; Poda G; Diamandis EP; Prassas I
    Clin Chem Lab Med; 2019 Oct; 57(11):1737-1743. PubMed ID: 31129650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
    J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity.
    Zhu Y; Underwood J; Macmillan D; Shariff L; O'Shaughnessy R; Harper JI; Pickard C; Friedmann PS; Healy E; Di WL
    J Allergy Clin Immunol; 2017 Nov; 140(5):1310-1322.e5. PubMed ID: 28238749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
    Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
    J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin.
    Ulbricht D; Tindall CA; Oertwig K; Hanke S; Sträter N; Heiker JT
    Biol Chem; 2018 Sep; 399(9):1079-1084. PubMed ID: 29494334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Human Kallikrein 5 Protease by Triterpenoids from Natural Sources.
    Matsubara Y; Matsumoto T; Koseki J; Kaneko A; Aiba S; Yamasaki K
    Molecules; 2017 Oct; 22(11):. PubMed ID: 29077044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
    Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
    Chen W; Kinsler VA; Macmillan D; Di WL
    PLoS One; 2016; 11(11):e0166268. PubMed ID: 27824929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.
    de Souza AS; Pacheco BDC; Pinheiro S; Muri EMF; Dias LRS; Lima CHS; Garrett R; de Moraes MBM; de Souza BEG; Puzer L
    Bioorg Med Chem Lett; 2019 May; 29(9):1094-1098. PubMed ID: 30833107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
    de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
    Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.
    Teixeira TS; Freitas RF; Abrahão O; Devienne KF; de Souza LR; Blaber SI; Blaber M; Kondo MY; Juliano MA; Juliano L; Puzer L
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6112-5. PubMed ID: 21903387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases.
    Stefansson K; Brattsand M; Roosterman D; Kempkes C; Bocheva G; Steinhoff M; Egelrud T
    J Invest Dermatol; 2008 Jan; 128(1):18-25. PubMed ID: 17625593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
    White GV; Edgar EV; Holmes DS; Lewell XQ; Liddle J; Polyakova O; Smith KJ; Thorpe JH; Walker AL; Wang Y; Young RJ; Hovnanian A
    Bioorg Med Chem Lett; 2019 Mar; 29(6):821-825. PubMed ID: 30691925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5.
    Hoelz LVB; Zorzanelli BC; Azevedo PHRA; Passos SG; de Souza LR; Zani M; Pinheiro S; Puzer L; Dias LRS; Muri EMF
    Eur J Med Chem; 2016 Apr; 112():39-47. PubMed ID: 26874743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
    J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
    Walker AL; Bingham RP; Edgar EV; Ferrie A; Holmes DS; Liddle J; Polyakova O; Rella M; Smith KJ; Thorpe JH; Wang Y; White GV; Young RJ; Hovnanian A
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1454-1458. PubMed ID: 31005442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant, antibacterial, and anti-inflammatory activities of standardized brazilin-rich Caesalpinia sappan extract.
    Nirmal NP; Panichayupakaranant P
    Pharm Biol; 2015; 53(9):1339-43. PubMed ID: 25864864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.
    Oliveira JP; Freitas RF; Melo LS; Barros TG; Santos JA; Juliano MA; Pinheiro S; Blaber M; Juliano L; Muri EM; Puzer L
    ACS Med Chem Lett; 2014 Feb; 5(2):128-32. PubMed ID: 24900785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.